HLB Life Science Co. Ltd (KQ:067630) — Market Cap & Net Worth
Market Cap & Net Worth: HLB Life Science Co. Ltd (067630)
HLB Life Science Co. Ltd (KQ:067630) has a market capitalization of $82.54 Million (₩121.79 Billion) as of September 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #20008 globally and #1047 in its home market, demonstrating a 2.77% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HLB Life Science Co. Ltd's stock price ₩2600.00 by its total outstanding shares 46842300 (46.84 Million). Also see 067630 current and non-current assets for a full breakdown of the balance sheet.
HLB Life Science Co. Ltd Market Cap History: 2015 to 2026
HLB Life Science Co. Ltd's market capitalization history from 2015 to 2026. Data shows change from $58.81 Million to $82.54 Million (-0.16% CAGR). Also see HLB Life Science Co. Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
HLB Life Science Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$233.34 Billion | 0.04% | #445 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$233.34 Billion | 0.04% | #445 of 1384 |
Weight: HLB Life Science Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
HLB Life Science Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HLB Life Science Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 067630 live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
HLB Life Science Co. Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.05x
HLB Life Science Co. Ltd's market cap is 0.05 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $58.81 Million | $27.32 Billion | -$17.04 Billion | 0.00x | N/A |
| 2016 | $77.26 Million | $42.23 Billion | -$1.25 Billion | 0.00x | N/A |
| 2017 | $112.80 Million | $106.45 Billion | $7.76 Billion | 0.00x | 0.01x |
| 2018 | $252.90 Million | $102.48 Billion | -$3.07 Billion | 0.00x | N/A |
| 2019 | $408.03 Million | $114.02 Billion | -$7.60 Billion | 0.00x | N/A |
| 2020 | $399.94 Million | $91.80 Billion | -$55.80 Billion | 0.00x | N/A |
| 2021 | $366.12 Million | $53.49 Billion | -$49.15 Billion | 0.01x | N/A |
| 2022 | $327.83 Million | $99.59 Billion | -$54.28 Billion | 0.00x | N/A |
| 2023 | $354.12 Million | $97.99 Billion | -$5.98 Billion | 0.00x | N/A |
| 2024 | $317.76 Million | $102.24 Billion | $6.14 Billion | 0.00x | 0.05x |
Competitor Companies of 067630 by Market Capitalization
Companies near HLB Life Science Co. Ltd in the global market cap rankings as of September 18, 2026. Review how tangible is HLB Life Science Co. Ltd's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to HLB Life Science Co. Ltd by market ranking:
- Sam Chun Dang Pharm. Co. Ltd (KQ:000250): Ranked #5752 globally with a market cap of $2.26 Billion USD ( ₩3.34 Trillion KRW).
- ST Pharm Co.Ltd (KQ:237690): Ranked #8322 globally with a market cap of $1.14 Billion USD ( ₩1.69 Trillion KRW).
- NatureCell Co.Ltd (KQ:007390): Ranked #9400 globally with a market cap of $895.63 Million USD ( ₩1.32 Trillion KRW).
- Oscotec Inc (KQ:039200): Ranked #10937 globally with a market cap of $654.17 Million USD ( ₩965.30 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #5752 | Sam Chun Dang Pharm. Co. Ltd | KQ:000250 | $2.26 Billion | ₩156100.00 |
| #8322 | ST Pharm Co.Ltd | KQ:237690 | $1.14 Billion | ₩90400.00 |
| #9400 | NatureCell Co.Ltd | KQ:007390 | $895.63 Million | ₩24900.00 |
| #10937 | Oscotec Inc | KQ:039200 | $654.17 Million | ₩34350.00 |
HLB Life Science Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, HLB Life Science Co. Ltd's market cap moved from $58.81 Million to $ 82.54 Million, with a yearly change of -0.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩82.54 Million | -32.90% |
| 2025 | ₩123.01 Million | -61.29% |
| 2024 | ₩317.76 Million | -10.27% |
| 2023 | ₩354.12 Million | +8.02% |
| 2022 | ₩327.83 Million | -10.46% |
| 2021 | ₩366.12 Million | -8.46% |
| 2020 | ₩399.94 Million | -1.98% |
| 2019 | ₩408.03 Million | +61.34% |
| 2018 | ₩252.90 Million | +124.21% |
| 2017 | ₩112.80 Million | +45.99% |
| 2016 | ₩77.26 Million | +31.38% |
| 2015 | ₩58.81 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of HLB Life Science Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $82.54 Million USD |
| MoneyControl | $82.54 Million USD |
| MarketWatch | $82.54 Million USD |
| marketcap.company | $82.54 Million USD |
| Reuters | $82.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About HLB Life Science Co. Ltd
HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendoc… Read more